Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
643 Views
Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...
680 Views
Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs
Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...
716 Views
Shanghai Henlius (复宏汉霖) IPO: Not an Impressive Biosimilar Portfolio
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In this insight, we will discuss the following topics: The...
1.1k Views
2018 HK-Connect SouthBound In a Nutshell
Since autumn of 2014, the HK-Shanghai Connect, and later the HK-Shenzhen Connect mechanisms have provided means for mainland investors to buy Hong...
690 Views